L'impact de la vaccination contre la coqueluche chez les adolescents, 20042009: les leçons données par l'Australie
Estudio en centros de atención al paciente para el diagnóstico de sarampión: detección de anticuerpos IgM y ácido nucleico viral específicos del sarampión
Helen E Quinn*; Peter B McIntyre
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Locked Bag 4001, Westmead, NSW, 2145, Australia
OBJECTIVE: To compare the impact of three strategies for delivering a booster dose of adult-formulated tetanusdiphtheriapertussis (Tdap) vaccine to adolescents in Australia. These comprise: (i) administering Tdap to: a one-year age cohort; (ii) administering Tdap to the entire high school and to subsequent entrant cohorts; and (iii) administering Tdap to the entire high school but without continuing to immunize entrant cohorts.
METHODS: A series of ecologic analyses of pertussis notifications during epidemic periods in relevant age cohorts were conducted. The primary outcome measure was the incidence rate ratio (IRR), calculated by dividing pertussis incidence after the introduction of Tdap delivery programmes by pertussis incidence during the most recent pre-programme epidemic.
FINDINGS: During the epidemic period of 20082009, the national-level IRR among age cohorts targeted for Tdap was 0.6 (95% confidence interval, CI: 0.60.7), but among other age cohorts it was 1.1 (95% CI: 1.11.2). Only the jurisdiction that implemented strategy 2 (Western Australia) experienced sustained decreases in pertussis notifications in both adolescents and infants under 6 months of age (IRR: 0.4; 95% CI: 0.30.6) until 2009.
CONCLUSION: If confirmed by longer experience in Australia and elsewhere, a broad school-based catch-up programme followed by immunization of school entrants may be the optimum strategy for the implementation of adolescent Tdap programmes.
OBJECTIF: Comparer l'impact de trois stratégies d'injection de rappel du vaccin tétanos-diphtérie-coqueluche (Tdap) formulé pour adulte chez des adolescents en Australie. Elles comprennent: (1) l'administration du Tdap à: une cohorte âgée d'un an; (2) l'administration du Tdap à tout le lycée et aux cohortes des nouveaux venus; (3) l'administration du Tdap à toute l'école, mais sans continuer à vacciner les cohortes des nouveaux venus.
MÉTHODES: On a réalisé une série d'analyses écologiques des notifications de la coqueluche lors des périodes d'épidémie dans les cohortes d'âges applicables. La principale mesure des résultats a été le rapport du taux d'incidence (RTI), calculé en divisant l'incidence de la coqueluche après l'introduction des programmes de vaccination du Tdap par l'incidence de la coqueluche lors de l'épidémie du préprogramme le plus récent.
RÉSULTATS: Lors de la période épidémique de 20082009, le RTI au niveau national chez les cohortes d'âges ciblées pour le Tdap était de 0,6 (intervalle de confiance de 95% IC: 0,60,7), mais chez les autres cohortes d'âges, il était de 1,1 (IC de 95%: 1,11,2). Seule la juridiction qui avait mis en place la stratégie 2 (Australie occidentale) a enregistré des baisses soutenues dans les notifications de la coqueluche chez les adolescents et les enfants de moins de 6 mois (RTI: 0,4; IC de 95%: 0,30,6) jusqu'en 2009.
CONCLUSION: S'il est confirmé par une plus longue expérience en Australie et partout dans le monde, un large programme de rattrapage au sein des écoles, suivi de la vaccination des nouveaux venus, pourrait être la stratégie optimale pour mettre en place les programmes de Tdap chez les adolescents.
OBJETIVO: evaluar el desempeño de un estudio en centros de atención al paciente recientemente desarrollado para la detección de anticuerpos IgM específicos del sarampión en muestras en suero y secreciones orales y evaluar si el ácido nucleico del virus del sarampión puede recuperarse de las tiras usadas en los estudios en centros de atención al paciente.
MÉTODOS: el estudio en centros de atención al paciente se utilizó para evaluar 170 muestras de suero recolectadas a través de programas de control o vacunación contra el sarampión en Etiopía, Malasia y la Federación de Rusia. Se obtuvieron 69 resultados positivos para anticuerpos de inmunoglobulina M (IgM) del sarampión, 74 resultados positivos para anticuerpos de IgM de rubéola y 7 resultados positivos para ambos. También se evaluaron 282 muestras de secreciones orales del programa de control del sarampión, paperas y rubéola del Reino Unido de Gran Bretaña e Irlanda del Norte. El inmunoensayo de enzimas IgM del sarampión microinmune fue el estándar de oro para la comparación. Se utilizó un panel de 24 secreciones orales para investigar si la hemaglutinina (H) del virus del sarampión y los genes nucleocápsides (N) podrían amplificarse por la reacción en cadena de polimerasa directamente de las tiras del estudio en centros de atención al paciente.
RESULTADOS: Con el suero, el estudio en centros de atención al paciente mostró una sensibilidad y especificidad del 90,8% (69/76) y 93,6% (88/94), respectivamente; con las secreciones orales, la sensibilidad y especificidad fueron del 90,0% (63/70) y 96,2% (200/208), respectivamente. Tanto los genes H como N fueron confiablemente detectados en las tiras del estudio en centros de atención al paciente y los genes N se pudieron secuenciar por genotipo. Los genes del virus del sarampión se recuperaron de las tiras del estudio en centros de atención al paciente después de estar almacenados durante 5 semanas a 20-25 ºC.
CONCLUSIÓN: El estudio en centros de atención al paciente tiene la sensibilidad y especificidad requeridas para un estudio de campo para el diagnóstico del sarampión. No obstante, su papel en los programas de control de sarampión a nivel global requiere una mayor evaluación.
Australia has seen large numbers of pertussis notifications in adolescents and adults over the past 10 to 15 years, as have some North American and European countries with long-standing high coverage for diphtheriatetanuspertussis (DTP) vaccines in childhood immunization programmes.13 DTP vaccines have been in general use in Australia since the 1950s,46 but because of concern about the possible adverse effects of the whole-cell pertussis component,7 during the 1970s and 1980s DTP vaccine was frequently substituted with diphtheriatetanus (DT) vaccine, and this led to a partially immunized cohort.8 Members of this cohort, which was also the last to not be eligible to receive the pre-school DTP booster added to the immunization schedule in 1994,9 figured prominently in successive epidemics between 1993 and 2002. A similar cohort effect has been observed in Canada.3 School outbreaks were also frequent at this time.10 Acellular vaccines replaced the Australian-manufactured wholecell vaccine for booster doses in 1997 and for all doses in 1999, and 95% coverage with three doses of this new vaccine (at 2, 4 and 6 months) by 2 years of age was attained within 4 years.11
The availability of a well formulated triple vaccine with an acellular pertussis component (Boostrix [Tdap], GlaxoSmith-Kline, Brentford, England) and the recognition that pertussis incidence in adolescents was increasing prompted the National Immunisation Programme to begin using Tdap on 1 January 2004 instead of the reduced antigen diphtheriatetanus (Td) booster dose previously recommended at age 15 to 17 years.12 Delivery of Tdap vaccine was primarily school-based, with limited doses also available in primary care.
Although several countries, including Canada, France, Germany and the United States of America, have added an adolescent booster dose to their list of recommended immunizations, reports of the impact of adolescent pertussis vaccine programmes has been limited to early and/or regional data.1317 The aim of this study was to compare the long-term impact of the approaches used in Australia vaccinating a one-year age cohort versus the entire high school, with and without continued immunization of high school entrants in the context of known historical differences in pertussis epidemic cycles by region.6 Our findings have implications for countries considering the introduction of Tdap boosters for children and adolescents 10 to 18 years of age.
We conducted a series of ecologic analyses of trends in pertussis notifications by age group, using relative incidence by time period, epidemic cycle and estimated vaccine coverage, to compare notification rates in relevant age cohorts. Data sources and methods of estimation for these analyses are described in the following sections.
Immunization programme managers from each Australian state and territory provided coverage data from school-based delivery programmes for the period between January 2004 and December 2009. No data were available on vaccines administered outside the school setting, but these were thought to represent a small proportion of the doses administered.
Pertussis notification before and after Tdap
Notifications to the National Notifiable Diseases Surveillance System with an onset date between 1 January 1999 and 31 December 2009 were eligible for this analysis. Pertussis cases are notifiable in every Australian jurisdiction under public health legislation. The criteria for notification are nationally uniform and include a combination of clinical, epidemiological and laboratory evidence. Laboratory evidence rests on culture of Bordetella pertussis or on the detection of B. pertussis by nucleic acid testing or single point serology. Since 1993, all public and private laboratories have been required to notify all persons testing positive on diagnostic tests for pertussis to public health authorities. Cases can be notified on clinical grounds alone if they report having had a coughing illness lasting 2 or more weeks and paroxysms of coughing, inspiratory whoop or post-tussive vomiting.18 However, over the past decade cases without laboratory evidence have become increasingly rare. We calculated notification rates for each age group and time period using average annual Australian Bureau of Statistics population estimates.19 We used the ratio of notification rates between epidemiologically relevant time periods (incidence rate ratios, IRRs) as the measure for comparison of programme impact, and we calculated their 95% confidence intervals (CIs) using a Poisson distribution.
With respect to programme delivery comparisons, we calculated incidence rate ratios (IRRs) using regional groupings based on differing programme delivery characteristics (Table 1). Three regions (Australian Capital Territory, South Australia and Victoria) applied strategy 1 delivery of the Tdap vaccine to a single school grade each year and formed a single programme grouping. The states of New South Wales and Western Australia delivered the vaccine to grades 7 up to 12 (ages 1219 years) in 2004, in the context of high pertussis notifications in adolescents in both regions. In New South Wales, this was followed by immunization of grade 7 students in 2005 and cessation of the programme for the following three years, before planned re-commencement of Tdap vaccine delivery to grade 10 students (strategy 2). In Western Australia, grade 7 students were immunized every year (strategy 3). In the state of Queensland there was little provision of free Tdap vaccine by private sector providers after 2003, but state-wide school-based immunization programmes targeting grade 10 students did not commence until 2007.
To account for the variability of programme delivery and vaccine coverage by age cohort and time period, we defined immunized and unimmunized cohorts among students aged 1219 years in each regional grouping above. As data on vaccination coverage were available by grade but not at the individual level, each grade was defined as vaccinated if the estimated Tdap vaccination coverage was 50% or higher. Grades not exposed to a schoolbased vaccination programme or where estimated vaccination coverage was less than 50% were considered unvaccinated. Data for Queensland for the years before commencement of a state-wide schoolbased programme were not included. As notification data were available by year of age, the single largest age group in each school grade (e.g. grade 7, 12 years; grade 8, 13 years; grade 9, 14 years, etc.) was used to generate an approximate incidence rate for each age group, defined as immunized or unimmunized as above, for calculation of the IRR (Table 2).
Overall, an estimated 1 066 000 of an estimated 1 650 000 eligible students aged 12 to 19 years (65%) received Tdap vaccine in school-based immunization programmes between January 2004 and December 2009. Annual coverage estimates were in the range of 55 to 76%, with coverage in subgroups of school grade and region varying from a low of 4% to a high of 85% (Table 1). However, estimated coverage within regions remained the same from year to year. In New South Wales and Western Australia, where the entire high school population was vaccinated within a single calendar year, higher coverage was obtained among younger students in the lower high school grades.
Pertussis notification before and after Tdap
By age group
Between 1 January 1999 and 31 December 2009, 110 602 cases of pertussis were notified nationally. Averaged data shows that national epidemics occurred in 2001, 20052006 and 20082009, but the exact timing differed in each region.6 Fig. 1 shows pertussis notification rates per 100 000 population over the 10-year period from 1999 to 2009, as well as IRRs for the 1219 age group in comparison to the remainder of the population. At the national level, 2001 was the year with the highest annual notification rate recorded for adolescents aged 1219 years (127.7 cases per 100 000 population). This decreased significantly to 31.1 cases per 100 000 population in the period from 2005 to 2007. Notification rates in the 1219 year age group remained significantly lower during the most recent epidemic (20082009) than during the 2001 epidemic, as shown by the 95% CIs for point estimates. This stood in contrast to the significant increases noted in all other age groups relative to 2001.
By period and programme delivery groupings
Table 3 shows the IRRs for regional groupings with varying programme delivery methods. In New South Wales, where the programme targeting the entire high school population achieved high coverage but was discontinued for three years, notification rates declined sharply at first but rose substantially in the 20082009 epidemic period. In Western Australia, where students entering high school continued to be vaccinated year after year after the entire high school population was vaccinated, notification rates also decreased rapidly but remained low to the end of 2009.
By cohort immunization status
Given the wide variation in programme roll-out by age group and timing of epidemic peaks in notifications across regions, we used notification rates in immunized and unimmunized age groups, as defined in the methods section, to generate IRRs for each region. Table 4 shows IRRs for both immunized and unimmunized cohorts during the most recent epidemic period (20082009) and during the period immediately following programme implementation (20052007). In the period 20052007 immediately following programme implementation, notification rates were significantly lower in immunized cohorts than in unimmunized cohorts in most programme delivery jurisdictional groupings, and the rates in both cohorts were lower than the rates recorded in the most recent pre-programme epidemic year. The only exception was the state of Queensland, where the Tdap programme was not implemented until 2007.
Based on overall notification rates, pertussis epidemics commenced during 20082009 in all regions, except in Western Australia. In all programme delivery groups the IRR in immunized age cohorts was again lower than in unimmunized cohorts. In the jurisdictional grouping where the programme was implemented in a single grade, the IRR during the 2008 2009 epidemic period rose but was not significantly higher than during the comparator pre-programme epidemic period. By contrast, in New South Wales, where the entire high school population was vaccinated within a one-year period but high school entrants were not for the following three years, a significantly higher IRR was seen in the unimmunized cohort (Table 4). In the immunized cohort the overall IRR was 0.87, in grade 10 students immunized during the epidemic the IRR was 1.60 (95% CI: 1.41.8) as opposed to 0.69 (95% CI: 0.60.8) in students immunized in 2004 and 2005. In Western Australia, where vaccination of the entire high school population was followed by immunization of each successive entrant cohort, no epidemic occurred in any age group in 20082009. Notably, the IRRs in immunized and unimmunized cohorts were similar, as in 20052007, and both were substantially lower than in the comparator epidemic period. In Queensland, incidence did not differ among immunized and unimmunized cohorts but was significantly lower in both groups after the Tdap vaccination programme was implemented.
Notification trends in young infants
The same regional programme delivery groupings were used to compare trends over time in pertussis notification rates among infants less than 6 months of age (Table 5). In 20052007, rates dropped significantly (by 2060%) in all groupings relative to the most recent pre-programme epidemic period. During the 20082009 epidemic, notification rates among infants less than 6 months of age returned to levels similar to those observed in the reference epidemic period with two exceptions. In New South Wales, notification rates in 20082009 were significantly higher, more than double what they were during the reference epidemic period, while in Western Australia notification rates were significantly lower, at around 40% of the rates reported in the most recent pre-programme epidemic.
In 2002, the Global Pertussis Initiative recommended that countries expand existing vaccination strategies to include a pertussis booster dose for adolescents.20 A recent meeting of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) noted that supporting data on cost-effectiveness for programmes targeting adolescents were lacking and that data on impact on infant disease were particularly relevant.21 Countries that have added an adolescent booster dose to their schedules since the 2002 recommendation include Canada, France, Germany, New Zealand and the United States.22 Timing of programme commencement has varied widely and data on disease reduction in the targeted age group are lacking. In this national evaluation, we have taken account of variations in vaccine delivery, programme implementation and pertussis epidemic cycles by region6 to estimate the impact of the programme on pertussis in the targeted age group. This study is the first to specifically evaluate impact in young infants.
With respect to vaccine coverage, individual level data were not available, as the Australian Childhood Immunisation Register only records vaccinations given up to the age of 7 years. We therefore relied on estimates of coverage derived from the school-based programme and on data supplied by each state and territory in varying detail and format. Overall, approximately 65% of the targeted age group was vaccinated up to the end of 2009, but coverage varied from 4% to 85% by age group and region. These are minimum estimates of population coverage, as no data were available for doses administered in the private sector. However, confidence in our estimates of 5080% is supported by their consistency with estimates from a similar Australian school-based meningococcal C conjugate vaccine catch-up programme in 2003,23 and with those from Canadian provinces immunizing school years 9 and 10 (14- to 16-year-olds).13,15 In the United States, Tdap was recommended for use in adolescents in 2006 but is not delivered through a school-based programme. Coverage estimates rose from 11% in 2006 to 30% in 2007, but, as in our data, they were significantly higher among adolescents aged 1314 years than among those aged 1517 years.24,25 Similarly, lower coverage in older high school students was observed in the Australian meningococcal C conjugate vaccine catch-up programme.23 This is probably because of more frequent absences from school among older students and lower school retention rates (81% for grades 1012)26 and is likely to be applicable in comparable developed country settings.
The use of pertussis notification data to measure impact from an adolescent Tdap programme is confounded by interannual and epidemic variations in pertussis activity, which we took into account in our analysis, as well as by changes in diagnostic practice. The impact of testing practices is substantial, as laboratories in Australia are mandated to notify positive results on pertussis diagnostic tests, whereas clinicians are known to be much less reliable notifiers, whether or not there is laboratory confirmation. Between 2001 and 2009, the proportion of notifications recorded in the NNDSS as confirmed by any laboratory method increased from 55% to 90%. This increase was largely driven by positives detected with polymerase chain reaction (PCR), since PCR had become increasingly available through community laboratories since 2007. The increase in PCR use among adolescents was greater in New South Wales than in other jurisdictions. This may have led to amplified increases in notification rates in this age group in that jurisdiction during 20082009 but should have had minimal impact on notifications in infants among whom PCR has been predominantly used as a diagnostic test since 2001.
Despite the limitations of the available data, the range of analytic methods that we used from aggregated age groups to smaller age subgroups and to regional groupings with differing vaccine coverage over time showed consistent evidence of an impact. The relatively low notification rate in 1219 year olds seen in 2004 was maintained until the 20082009 epidemic and the rate remained lower than during historical peaks. This was in marked contrast to what we observed in other age groups. When the data were further refined to consider immunized cohorts specifically, this trend is more clearly evident and is consistent with the early vaccine effectiveness estimates of 7885% for Tdap obtained in New South Wales in 2004.16 We were unable to estimate vaccine effectiveness in the current study because individual level data on vaccination status is lacking.
In Western Australia, the notification rate in the unimmunized cohort was nearly identical to the rate in the immunized cohort in 20082009. While disease activity in all age groups in Western Australia was low in 2008, this finding is consistent with herd immunity among the unimmunized adolescent cohort. The increased IRR in the immunized and unimmunized cohorts in New South Wales may be the result of waning immunity, as most of the immunized cohort had not been vaccinated since 2004 or 2005. However, more detailed analysis showed that grade 10 students, who were being vaccinated during the epidemic, had a higher IRR than the rest of the immunized cohort.
A key question is whether adolescent pertussis immunization programmes have any impact on pertussis transmission among young, unimmunized infants. In our data, there was a decrease in the notification rate among infants younger than 6 months of age following the initiation of adolescent pertussis immunization in the National Immunization Programme in 2004, but this was also seen in other age groups during the inter-epidemic period and was sustained until 20082009 only in Western Australia. Although this finding could be explained by more dispersed epidemic cycles in Western Australia,6 pertussis notification rates in that state did increase in 2010 (data not shown) and were high in children aged 59 and 1014 years; only 40% of the children aged 1014 years were eligible for Tdap. In contrast, in 2010 notifications remained low in Western Australia among 15- to 19-year-olds (all eligible for Tdap) and the IRR for infants aged 0 to 6 months was not appreciably different in 2010 than in 2009 (0.46 [95% CI: 0.300.69] versus 0.40 [95% CI: 0.280.57], respectively, Table 5), maintaining the differential with other jurisdictions.27
Although limited by its ecologic design, our analysis provides some evidence that a pertussis vaccination catch-up component has an impact on herd immunity and on the incidence of disease among infants. Catch-up programmes can rapidly reduce pertussis incidence across a broad range of ages and ongoing immunization of children entering adolescence may be important for maintaining this in the long term. The consistently higher notification rates in younger adolescents also suggest that the programme should target younger age groups. Targeting a programme to younger people will have follow-up implications for countries considering cocooning recommendations for new parents, which must factor in the waning of antibody levels between adolescence and pregnancy. The most recent data suggest that antibody levels have dropped substantially by the tenth year after immunization.28
In conclusion, data from Australia demonstrate that school-based adolescent pertussis vaccination programmes can achieve high coverage relatively rapidly and have a demonstrable impact on the incidence of pertussis, as measured by case notifications. Our experience suggests that, in the context of school-based delivery, implementing a broadly based vaccination programme is more beneficial than introducing the vaccine in a single school year, but that it is necessary to immunize children entering high school on an ongoing basis. This is particularly important if it is shown that broad-based catch-up immunization of adolescents effectively decreases the incidence of severe disease in unimmunized infants.
We wish to acknowledge the contributions of the state and territory government immunization programme managers and staff. We also wish to acknowledge the contributions of the Communicable Diseases Network Australia.
Funding: This work was supported by the Australian Government Department of Health and Ageing, the New South Wales Department of Health and The Children's Hospital at Westmead.
Competing interests: None declared.
1. America Academy of Pediatrics Commitee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 2006;117:96578. doi:10.1542/peds.2005-3038 PMID:16382131
2. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005;24:7615. doi:10.1097/01.inf.0000177282.53500.77 PMID:16148840
3. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003;22:227. doi:10.1097/00006454-200301000-00009 PMID:12544404
4. Gidding HF, Burgess MA, Kempe AE. A short history of vaccination in Australia. Med J Aust 2001;174:3740. PMID:11219791
5. Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004;22:218191. doi:10.1016/j.vaccine.2003.11.053 PMID:15149775
6. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 19952005 trends by region and age group. Commun Dis Intell 2007;31:20515. PMID:17724997
7. MacIntyre CR, Nolan T. Attitudes of Victorian vaccine providers to pertussis vaccine. Med J Aust 1994;161:2934. PMID:7830662
8. Brotherton J, McAnulty J. A pertussis epidemic in NSW: how epidemiology reflects vaccination policy. N S W Public Health Bull 2003;14:7781. doi:10.1071/NB03024 PMID:12806405
9. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 2003;22:9569. doi:10.1097/01.inf.0000095198.75170.b6 PMID:14614366
10. Horby P, Macintyre CR, McIntyre PB, Gilbert GL, Staff M, Hanlon M et al. A boarding school outbreak of pertussis in adolescents: value of laboratory diagnostic methods. Epidemiol Infect 2005;133:22936. doi:10.1017/S0950268804003401 PMID:15816147
11. Hull BP, Mahajan D, Dey A, Menzies RI, McIntyre PB. Immunisation coverage annual report, 2008. Commun Dis Intell 2010;34:24158. PMID:21090180
12. National Health and Medical Research Council. The Australian immunisation handbook. Canberra: Australian Government Department of Health and Ageing; 2003.
13. David ST, Hemsley C, Pasquali PE, Larke B, Buxton JA, Lior LY. Enhanced surveillance for vaccine-associated adverse events: dTap catch-up of high school students in Yukon. Can Commun Dis Rep 2005;31:11726. PMID:15940837
14. Disease Control and Epidemiology Newfoundland & Labrador Department of Health and Community Services. Pertussis in Newfoundland and Labrador: 19912004. Can Commun Dis Rep 2005;31:2357. PMID:16669124
15. Kandola K, Lea A, White W, Santos M. A comparison of pertussis rates in the Northwest Territories: Pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol 2005;16:2714. PMID:18159557
16. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009;28:1523. doi:10.1097/INF.0b013e318185608e PMID:19106780
17. Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006;24:59605. doi:10.1016/j.vaccine.2006.05.011 PMID:16757063
18. Interim surveillance case definitions for the Australian National Notifiable Diseases Surveillance System, Version 1. 1 [Internet]. Canberra: Australian Government, Department of Health and Ageing; 2004. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-distype.htm[accessed 17 June 2011].
19. Population by age and sex, Australian states and territories [Internet]. Canberra: Australian Bureau of Statistics; 2009. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/second+level+view?ReadForm&prodno=3201.0&viewtitle=Population%20by%20Age%20and%20Sex [accessed 17 June 2011].
20. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007;25:263442. doi:10.1016/j.vaccine.2006.12.017 PMID:17280745
21. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2010 - conclusions and recommendations. Wkly Epidemiol Rec 2010;85:197212. PMID:20514734
22. WHO Vaccine Preventable Diseases Monitoring System [Internet]. Geneva: World Health Organization; 2011. Available from: http://apps.who.int/immunization_monitoring/en/globalsummary/DiseaseSelect.cfm?U=years [accessed 17 June 2011].
23. Ward KF, Menzies RI, Quinn HE, Campbell-Lloyd S. School-based vaccination in NSW. N S W Public Health Bull 2010;21:23742. doi:10.1071/NB10046 PMID:21211477
24. Centers for Disease Control and Prevention (CDC). Vaccination coverage among adolescents aged 1317 years - United States, 2007. MMWR Morb Mortal Wkly Rep 2008;57:11003. PMID:18846032
25. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 1317 years United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:9971001. PMID:19763075
26. 4221.0 Schools, Australia [Internet]. Canberra: Australian Bureau of Statistics; 2010. Available from: http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/0014934D84F64006CA2578550011905F/$File/nssc%20table%2064a%20apparent%20retention%20rates,%201996_2010.xls [accessed 17 June 2011].
27. National communicable diseases surveillance report: fortnight 25, 2010 summary notes for selected diseases, 4 to 17 December 2010. Canberra: Office of Health Protection, Surveillance Branch; 2010. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/010561D59E66FCCACA2578020013CB45/$File/nndssreport-fn25-10.pdf [accessed 17 June 2011].
28. Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010;51:65662. [REMOVED HYPERLINK FIELD] doi:10.1086/655825 PMID:20704493
(Submitted: 26 January 2011 Revised version received: 8 June 2011 Accepted: 13 June 2011 Published online: 5 July 2011)